Onconetix (ONCO) Expected to Announce Earnings on Thursday

Onconetix (NASDAQ:ONCO) is expected to announce its Q3 2026 results on Thursday, November 12th. Analysts expect Onconetix to announce earnings of ($45,050.00) per share and revenue of $0.02 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Onconetix (NASDAQ:ONCO) last released its quarterly earnings data on Thursday, August 13th. The company reported ($12.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($45,050.00) by $45,037.20. Onconetix had a negative net margin of 1,575.89% and a negative return on equity of 91.95%. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million.

Onconetix Stock Down 3.1%

Shares of NASDAQ ONCO opened at $3.47 on Wednesday. Onconetix has a twelve month low of $3.15 and a twelve month high of $1,610.00. The firm has a market cap of $2.04 million, a P/E ratio of 0.00 and a beta of 2.62. The company has a 50 day moving average of $6.45 and a 200 day moving average of $121.92.

Analyst Ratings Changes

Several analysts have commented on ONCO shares. Wall Street Zen upgraded Onconetix from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings upgraded Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Onconetix Company Profile

Onconetix, Inc. is a biotechnology company focused on developing and commercializing diagnostic and therapeutic products for men’s health. The company’s portfolio is centered primarily on prostate health, with products intended to support the detection, risk assessment and treatment of prostate-related conditions. Its lead diagnostic product is Proclarix, a blood-based test designed to help assess the risk of clinically significant prostate cancer in men with elevated prostate-specific antigen (PSA) levels.